Midazolam

Class Sedative
Chemistry

Benzodiazepine

Routes of administration

IV, IM, subcutaneously, intranasally buccaly and orally (though the oral dose required is about doubled)

Absorption

44% bioavauilability; well absorbed, but also undergoes significant first-pass metabolism

Solubility

pKa 6.7; good water solubility at pH <4 (as a hydrochloride salt) -0 when injected, it becomes lipid-soluble at physiologic pH

Distribution

VOD = 0.8 to 1.5 L/kg; 96% protein bound

Metabolism

Hepatic metabolism to α-hydroxymidazolam (which is active), and then an inactive renally excreted glucouronide. α-hydroxymidazolam can accumulate in renal failure

Elimination

Both the active metabolite and the inactive glucouronide are renally excreted

Time course of action

Redistribution half-life is 15 minutes; elimination half-life is 1.5-3.5 hours

Target receptor

GABA-A channel (a separate binding site from GABA)

Mechanism of action

Allosteric modulator of the GABA-A receptor: acts on GABA-A chloride channels, where it binds to a site distinct from the GABA binding site, and potentiates the effects of GABA, this increasing the chloride current and hyperpolarising the cell membrane of the neuron

Clinical effects

Sedation, amnesia, anticonvulsant effect, mild decrease in cerebral oxygen demand, no effect on ICP.
Respiratory response to raised CO2 is flattened, but respiratory drive is not as suppressed as it would be with opioids. Airway reflexes are depressed.
Haemodynamic effects (decreased blood pressure and heart rate) are related to its suppression of the sympathetic nervous system. These are less pronounced than those of propofol.

Literature reference

Okkola & Ahonen (2008)

CICM details of understanding Level 1
Mentioned around Deranged Physiology
Related SAQs

Question 1 from the second paper of 2022 (midazolam alone)

Question 9 from the second paper of 2019 (propofol vs midazolam)

Question 7 from the first paper of 2019 (midazolam vs. dexmedetomidine)

Question 4 from the second paper of 2018 (ketamine vs midazolam)

Question 24 from the first paper of 2016 (midazolam vs. the “ideal” agent)